A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

NCT07663318 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: T25-Fast
DRUG: Mycapssa
DRUG: T25-Fed

Sponsor

Triastek (Shanghai) Limited

Collaborators

[object Object]